Cargando…
Liquid Biopsy for Guiding Treatment Decisions in Advanced Non–Small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related deaths in the United States. The 5-year survival rates are poor with traditional therapy alone. New scientific advances in technology involving the human genome, including diagnostic tools to inform on tumor-derived acquired (somatic) mutations that...
Autor principal: | Suk, Gretchen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881738/ https://www.ncbi.nlm.nih.gov/pubmed/36727019 http://dx.doi.org/10.6004/jadpro.2022.13.8.5 |
Ejemplares similares
-
The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer
por: Saarenheimo, Jatta, et al.
Publicado: (2019) -
The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer
por: Akhoundova, D., et al.
Publicado: (2020) -
Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer
por: Pesta, Martin, et al.
Publicado: (2022) -
Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges
por: Rijavec, Erika, et al.
Publicado: (2019) -
Liquid Biopsy in Non-Small Cell Lung Cancer
por: Molina-Vila, Miguel A., et al.
Publicado: (2016)